CJC-1295 With DAC

The long-acting version of CJC-1295 that maintains elevated GH levels throughout the week via Drug Affinity Complex technology binding to albumin.

The Drug Affinity Complex binds albumin, extending circulating half-life to around eight days and producing sustained GHRH receptor stimulation rather than a sharp pulse.

Where CJC-1295 No DAC creates a sharp GH pulse, the DAC version provides sustained background elevation of GH throughout the week. Different application, different protocol.

• Sustained serum GH levels
• IGF-1 baseline elevation
• Body composition over weeks
• Recovery markers

• Sustained GH and IGF-1 elevation
• Body composition across extended protocols
• Recovery and tissue repair
• Albumin-binding pharmacokinetics

Created by adding a Drug Affinity Complex to the modified GRF 1-29 backbone, dramatically extending circulating half-life.

Men and women 35-65 seeking sustained GH elevation rather than pulsatile release.

• Reconstitute with bacteriostatic water down the vial wall.
• Swirl gently until fully dissolved.
• 8-day half-life, model accumulation carefully.
• Store lyophilised at -20C, reconstituted at 4C.
• Avoid freeze-thaw cycles.

• Sustained elevation blunts natural pulsatility, a key protocol difference.
• Long half-life means slow onset and slow washout.
• Frequently compared against the No DAC variant in literature.
• Often paired with a selective secretagogue.